patent.fyi
Applications  /  US 2026/0356860
United States Patent Application Publication

US 2026/0356860 A1

Published
Nov 12, 2026
Filed
Oct 18, 2023
Earliest date on the face
Oct 18, 2022
Classification
C07F 5/025
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Carboxyl group at R1

What ifWhat if R1 carries a carboxyl group?
Claim language“or —B(OH)2”

The carboxyl carbon bonds directly to the scaffold at R1. The two oxygen atoms provide hydrogen-bonding sites and share the negative charge when the group is deprotonated.

1.3Pyridine as the carrier ring

What ifWhat if a pyridine ring carries R3?
Claim language“phenyl substituted with R3”

A 5-cyanopyridin-2-yl group bonds to the scaffold through pyridine C2 and carries cyano at C5. The two attachment sites lie across the planar ring from one another, and the pyridine nitrogen provides a hydrogen-bond acceptor.

1.5Fused carbocyclic carrier for R3

What ifWhat if a naphthalene ring system carries R3?
Claim language“5- or 6-membered heteroaryl substituted with R3”

A 6-cyanonaphthalen-2-yl group bonds to the scaffold at C2 and carries cyano at C6. The fused carbon rings hold the two attachments in a rigid aromatic plane.

1.6Cyclohexane as the distal ring

What ifWhat if a trans-1,4-disubstituted cyclohexane carries R3 on the far side of the heteroaryl ring?
Claim language“substituted with -phenyl-R3”

A pyridine carbon bonds directly to cyclohexane C1, and a cyano group bonds to cyclohexane C4. The trans configuration allows both substituents to occupy equatorial positions in the same chair conformation.

1.8Oxygen in the carrier ring

What ifWhat if a saturated six-membered ring containing oxygen carries R3?
Claim language“C3-C6cycloalkyl substituted with R3”

A 4-cyanooxan-4-yl group bonds to the scaffold through C4, which also bears cyano. The ring adopts a chair conformation, and the oxygen opposite C4 provides a hydrogen-bond acceptor.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference mixtures for analytical training

An analytical training kit uses thiopyranopyrimidinone derivatives bearing cyano, fluoro, or trifluoromethyl groups on the same phenyl attachment. Individual stock solutions establish retention times and mass signals by liquid chromatography coupled to mass spectrometry. A mixed sample lets trainees assign peaks by matching both measurements to the individual references.

Component substitution

Sulfur dioxide in the fused ring

A sulfone replaces the thioether in the six-membered sulfur-containing ring of the fused pyrimidinone scaffold. The ring sulfur retains both carbon bonds and carries two oxygen atoms. Oxidation with excess meta-chloroperbenzoic acid converts the isolated thioether to the sulfone, and liquid chromatography coupled to mass spectrometry tracks the sulfoxide intermediate and sulfone product.

Vinyl linker replacement with ethylene

A two-carbon ethylene linker replaces the vinyl linker between C2 of the thiopyranopyrimidinone core and the terminal aryl ring. For a cyano-substituted phenyl derivative, the corresponding 3-(cyanophenyl)propanimidamide supplies the saturated side chain during condensation with a cyclic beta-keto ester that supplies the sulfur-containing ring. Proton nuclear magnetic resonance identifies the two linker methylene groups in the isolated product.

Parameter or scale variation

Twelve-member positional isomer panel

A screening panel contains 12 derivatives with a common thiopyranopyrimidinone core and a phenyl group attached at C2. Each phenyl ring carries one of four substituents, fluoro, chloro, cyano, or trifluoromethyl, at the 2-, 3-, or 4-position relative to its attachment to the core. The plate holds each derivative in duplicate at 1, 3, 10, and 30 micromolar, with a matched solvent concentration across wells.

Combination with existing systems

Hydrogel dressing with a drug reservoir

A porous wound-contact layer supports a crosslinked hydrogel reservoir containing a dispersed thiopyranopyrimidinone derivative, and a backing film covers the outer face. Water entering from the contact side hydrates the gel and dissolves part of the compound. The dissolved fraction diffuses through the contact layer, and a diffusion cell with a buffered receiver measures cumulative release by liquid chromatography.

Automated or data-driven variant

Image analysis for cell migration

An automated microscope images confluent keratinocyte cultures after a uniform gap is introduced in each well and a liquid handler dispenses thiopyranopyrimidinone derivatives. Image analysis software segments the cell-free area and expresses its change as a fraction of the starting area. The software reports time courses by dose alongside vehicle controls and pairs each course with an endpoint viability measurement.

Specific version of a part

Deuterium at R1a

A single deuterium atom occupies R1a. The bond at that position has a lower stretching frequency than the corresponding bond to protium.

Phenyl linked to cyanopyridine

The scaffold bonds to C1 of a phenyl ring, and phenyl C4 bonds directly to C2 of a pyridine ring. Pyridine C5 carries cyano as R3, and phenyl C2 carries fluorine as R3a.

Thiophene linked to cyanopyridine

Thiophene C2 bonds to the scaffold, and thiophene C5 bonds directly to pyridine C2. Pyridine C5 carries cyano as R3, and thiophene C3 carries methyl as R3a.

Cyclohexane bearing chlorophenyl

Cyclohexane C1 bonds to the scaffold, and C4 bears a 4-chlorophenyl group with chlorine as R3. The two cyclohexane substituents have a trans relationship and occupy equatorial positions in the same chair conformation.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,034,041 B2
Published
Apr 25, 2006
Filed
Mar 7, 2003
Document BUS 11,352,322 B2
Published
Jun 7, 2022
Filed
May 8, 2017
Class
C07D 205/12
Claim 1
Document A
Document B
1.1R1 is hydrogen, deuterium, C1-C3alkyl, —OH, —O—C1-C3alkyl, —CH2OH, or —B(OH)2
R1 is selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo (═O), thioxo (═S), —SO2—, amino, hydrazino, formyl, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, C7-12 arylalkoxy, C3-8 cycloalkyl, C3-8 cycloalkyloxy, C5-6 aryl, C2-10 heterocyclyl, C1-6 heteroaryl, alkylamino, —COORa, —C(O)Rb, —C(S)Ra, —C(O)NRaRb, —C(S)NRaRb, —NRaC(O)NRbRc, NRaC(S)NRbRc, —N(Ra)SORb, —N(Ra)SO2Rb, —NRaC(O)ORb, —NRaRb, —NRaC(O)Rb—, —NRaC(S)Rb—
B · US 11,352,322 B2 · ¶ 14
1.2R1a is hydrogen, deuterium, or C1-C3alkyl
1.3R2 is (a) phenyl substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups
A substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine compound of formula I, wherein R1 denotes a branched or unbranched C1–C5-alkyl, a halogen other than chlorine at the 4-position, a branched or unbranched O—C1–C5-alkyl, a branched or unbranched S—C1–C5-alkyl, or a salt thereof of a physiologically compatible acid.
A · US 7,034,041 B2 · claim 1
1.4(b) phenyl substituted with 5- or 6-membered heteroaryl where the 5- or 6-membered heteroaryl is substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups and where the phenyl is additionally optionally substituted with 1, 2, or 3 R3a groups, (c) phenyl optionally substituted with 1, 2, or 3 R3a groups and additionally substituted with -phenyl-R3 where the phenyl in -phenyl-R3 is optionally substituted with 1, 2, or 3 R3a groups
1.5(d) 5- or 6-membered heteroaryl substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups
R2 is selected from the group consisting of —OR7, aniline, amino C5-6 aryl, and amino C1-6 heteroaryl, wherein aniline, amino C5-6 aryl, and amino C1-6 heteroaryl, is optionally substituted with one or more of the groups selected from C1-8 alkyl, halogen, OH, amino, and cyano;
B · US 11,352,322 B2 · ¶ 14
1.6(e) 5- or 6-membered heteroaryl optionally substituted with 1, 2, or 3 R3a groups and additionally substituted with -phenyl-R3 where the phenyl is additionally optionally substituted with 1, 2, or 3 R3a groups
1.7(f) 5- or 6-membered heteroaryl optionally substituted with 1, 2, or 3 R3a groups and additionally substituted with -(5- or 6-membered heteroaryl)-R3 where the 5- or 6-membered heteroaryl in -(5- or 6-membered heteroaryl)-R3 is optionally substituted with 1, 2, or 3 R3a groups
1.8(g) C3-C6cycloalkyl substituted with R3 and additionally optionally substituted with 1 or 2 R3a groups
Y is a bond or is selected from the group consisting of substituted or unsubstituted C1-8 alkyl, C1-8 alkenyl, C1-8 alkynyl, C5-6 aryl, C1-6 heteroaryl, C2-10 heterocyclyl, C3-8 cycloalkyl, —CO—, and —CO—C2-10 heterocyclyl; wherein C1-8 alkyl, C5-6 aryl, C1-6 heteroaryl, C2-10 heterocyclyl, C3-8 cycloalkyl, is optionally substituted with one or more of the groups selected from hydrogen, C1-6 alkyl, oxo (═O), C3-8 cycloalkyl, halogen, OH, and cyano;
B · US 11,352,322 B2 · ¶ 14
1.9(h) C3-C6cycloalkyl substituted with 5- or 6-membered heteroaryl where the 5- or 6-membered heteroaryl is substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups, and where the cycloalkyl is optionally substituted with 1 or 2 R3a groups
1.10(i) C3-C6cycloalkyl substituted with phenyl where the phenyl is substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups, and where the cycloalkyl is optionally substituted with 1 or 2 R3a groups
Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine (compounds), methods for the production thereof, pharmaceutical compositions containing said compounds, and methods of treatment of pain and other diseases using the pharmaceutical compositions.
A · US 7,034,041 B2 · abstract
1.11(j) 3- to 8-membered heterocycloalkyl substituted with phenyl or substituted with 5- or 6-membered heteroaryl, where the phenyl and the 5- to 6-membered heteroaryl are substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups
1.12(k) —CH═CH—R5 where R5 is phenyl or 5- or 6-membered heteroaryl, where the phenyl and the 5- or 6-membered heteroaryl are substituted with R3 and additionally optionally substituted with 1, 2, or 3 R3a groups R3 is independently selected from —B(OH)2, cyano, halo, halo-C1-C6alkyl, —(C0-C6alkylene)-O—R4, or 5- to 10-membered heterocyclic wherein the 5- to 10-membered heterocyclic is optionally substituted with cyano or when R2 is (a), then R3 and one R3a, when on adjacent carbons, together with the carbons to which they are attached form where the * indicate the carbons shared with the phenyl ring and where the remaining optional R3a on the phenyl portion are as defined below, and each R7a is independently hydrogen or C1-C6alkyl each R3a is independently selected from cyano, halo, —OH, C1-C6alkyl, halo-C1-C6alkyl, and C1-C6alkoxy R4 is hydroxy-C1-C6alkyl, C1-C6alkoxy-C1-C6alkyl, or C1-C6alkoxycarbonyl-NH—C1-C6alkyl provided that the compound is not 2-(4-(trifluoromethyl)phenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(4-(4-methoxyphenyl)piperazin-1-yl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(4-(2-methoxyphenyl)piperazin-1-yl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(4-chlorophenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof, 2-(5-(trifluoromethyl)pyridin-2-yl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(3-(trifluoromethyl)phenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof, a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof 2-(3-(trifluoromethyl)phenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof, a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof or 2-(5-chlorothiophen-3-yl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one or a single stereoisomer or mixture of stereoisomers thereof a single tautomer or mixture of tautomers thereof and/or a pharmaceutically acceptable salt thereof.
According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, which is selected from a group consisting of: 1) (E)3(4(((2(4-Cyclopropylphenyl)cyclopropyl)amino)methyl)phenyl)-N-hydroxyacrylamide TFA salt 2) (E)-3-(4-{[2-(4-Fluoro-phenyl)-cyclopropylamino]-
B · US 11,352,322 B2 · ¶ 183

An empty cell means only that no passage was reproduced there.

Statements in these documents
Pain is one of the main symptoms in clinical practice, and there is a worldwide demand for effective pain treatment.
A · US 7,034,041 B2 · ¶ 3
The invention relates to substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridines, a process for their production, medicaments containing these compounds, the use of these substances for the production of medicaments as well as method for treating pain using the medicaments.
A · US 7,034,041 B2 · ¶ 2
The compounds described herein are dual inhibitors of lysine specific demethylase (LSD) and histone deacetylase (HDAC) and also arrest cell growth in neoplastic cells, thereby inhibiting proliferation.
B · US 11,352,322 B2 · ¶ 3
These compounds can be used as prophylactic or therapeutic agents for treating cancer, schizophrenia, Alzheimer's disease, Parkinson's disease, and the like.
B · US 11,352,322 B2 · ¶ 3
Cite aspatent.fyi, US 2026/0356860 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356860/, SHA-256 ff1fe632e4fda393df2db486339368c5a87cf087a2f94f87294cb77626b2073d
First published
Permanent addresshttps://patent.fyi/US20260356860/
Content fingerprint (SHA-256)ff1fe632e4fda393df2db486339368c5a87cf087a2f94f87294cb77626b2073d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi